

TABLE OF CONTENTS

0. Executive Summary	15
1. Basics of Drug Delivery to the Central Nervous System	17
Introduction	17
Historical evolution of drug delivery for CNS disorders.....	17
Neuroanatomical and neurophysiological basis of drug delivery.....	18
The cerebrospinal fluid	18
The extracellular space in the brain	19
Neurotransmitters.....	19
Neuropharmacology relevant to drug delivery.....	21
Introduction to neuropharmacology.....	21
Pharmacokinetics.....	21
<i>Absorption and distribution of drugs</i>	<i>21</i>
<i>Drug metabolism and elimination.....</i>	<i>22</i>
Pharmacodynamics	22
<i>Receptors</i>	<i>22</i>
Sites of drug action in the CNS	22
<i>Receptors coupled to guanine nucleotide binding proteins</i>	<i>23</i>
<i>Acetylcholine receptor channels</i>	<i>23</i>
<i>Dopamine receptors</i>	<i>23</i>
<i>GABA receptor channels.....</i>	<i>24</i>
<i>Glutamate receptor channels.....</i>	<i>24</i>
<i>Non-competitive NMDA antagonists.....</i>	<i>24</i>
<i>Serotonin receptors.....</i>	<i>25</i>
<i>G-protein coupled receptors</i>	<i>25</i>
In vivo study of drug action in the CNS in human patients	25
<i>Electroencephalography.....</i>	<i>25</i>
<i>Brain imaging.....</i>	<i>26</i>
Chronopharmacology as applied to the CNS	26
2. Blood Brain Barrier	29
Introduction	29
Features of the blood-brain barrier relevant to CNS drug delivery.....	29
The neurovascular unit	29
Functions of the BBB	30
<i>BBB as an anatomical as well as physiological barrier</i>	<i>30</i>
<i>BBB as a biochemical barrier</i>	<i>31</i>
Role of shear stress on development of BBB.....	31
Genomics of BBB	32
Proteomics of BBB.....	32
Other neural barriers	33
Blood-cerebrospinal fluid barrier	33
Blood nerve barrier	33
Blood-retinal barrier	34
Blood-labyrinth barrier	34
Passage of substances across the blood-brain barrier	34
Transporters localized in the BBB.....	34
<i>Glucose transporter.....</i>	<i>35</i>
<i>Amino acid transporters.....</i>	<i>36</i>
<i>Ionic transporter.....</i>	<i>36</i>
<i>Afflux transport systems</i>	<i>36</i>
BBB-specific enzymes.....	37
Receptor-mediated transcytosis	38
Lysophosphatidic acid-mediated increase in BBB permeability	38
Folate transport system	39
Molecular biology of the BBB	39
Transport of peptides and proteins across the BBB.....	39
<i>Passage of leptin across the BBB.....</i>	<i>39</i>
<i>Passage of cytokines across the BBB</i>	<i>40</i>
<i>Passage of hormones across the BBB</i>	<i>40</i>
<i>Passage of enzymes across the BBB</i>	<i>41</i>
<i>Drugs that cross the BBB by binding to plasma proteins.....</i>	<i>41</i>
Current concepts of the permeability of the BBB	41
Factors that increase the permeability of the BBB	42
BBB disruption as an adverse effect of pharmaceuticals	42
BBB disruption as adverse effect of vaccines for CNS disorders	43
Effect of CNS disorders on BBB	43

Autoimmune disorders.....	44
Brain tumors.....	44
<i>Primary brain tumors.....</i>	44
<i>Cerebral metastases.....</i>	44
Central nervous system injuries.....	45
Cerebrovascular disease.....	45
Epilepsy.....	46
Infections.....	46
Mitochondrial encephalopathies.....	47
Multiple sclerosis.....	47
Neurodegenerative disorders.....	47
Testing permeability of the BBB.....	49
In vitro models of BBB.....	49
In vivo study of BBB.....	50
<i>Brain imaging.....</i>	50
In silico prediction of BBB.....	51
Relevance of the BBB penetration to pharmacological action.....	52
<i>BBB penetration and CNS drug screening.....</i>	52
<i>CERENSESM.....</i>	53
Transthyretin monomer as a marker of blood-CSF barrier disruption.....	53
Evaluation of BBB permeability by brain imaging.....	53
Biomarkers of disruption of blood-brain barrier.....	53
Future directions for research on the BBB.....	54
Use of neural stem cells to construct the blood brain barrier.....	55
Strategies to cross the BBB.....	55

3. Methods of Drug Delivery to the CNS.....	57
Introduction.....	57
Routes of drug delivery to the brain.....	58
Delivery of drugs to the brain via the nasal route.....	58
<i>Passage of viruses to the brain via the nasal route.....</i>	59
<i>Potential and limitations of nasal drug delivery to the brain.....</i>	59
<i>Nasal delivery of insulin-like growth factor-I.....</i>	60
<i>Nasal delivery of midazolam.....</i>	60
<i>Nasal delivery of hypocretin.....</i>	60
<i>Nasal administration of IFN beta-1b.....</i>	61
<i>Nasal administration of erythropoietin.....</i>	61
<i>Nasal delivery of thyrotropin-releasing hormone by nanoconstructs.....</i>	61
<i>Nasal delivery of neuroprotective drugs for stroke.....</i>	62
Transdermal drug delivery for neurological disorders.....	62
Drug delivery to the brain via inner ear.....	62
Invasive neurosurgical approaches.....	63
<i>Intraarterial drug delivery to the brain.....</i>	63
<i>Direct injection into the CNS substance or CNS lesions.....</i>	64
<i>Targeted delivery of biologicals to the spinal cord by microinjection.....</i>	64
<i>Intraventricular injection of drugs.....</i>	64
<i>Intrathecal drug delivery.....</i>	65
<i>Retrograde delivery to the brain via the epidural venous system.....</i>	66
<i>Devices for drug delivery to the CNS.....</i>	67
Strategies for drug delivery to the CNS across the BBB.....	68
Increasing the permeability (opening) of the BBB.....	68
<i>Osmotic opening of the BBB.....</i>	68
<i>Focal disruption of BBB by ultrasound.....</i>	69
<i>Chemical opening of the BBB.....</i>	69
<i>Cerebral vasodilatation to open the BBB.....</i>	69
<i>Modulation of vascular permeability by laser irradiation.....</i>	70
<i>Use of nitric oxide donors to open the BBB.....</i>	70
<i>Manipulation of the sphingosine 1-phosphate receptor system.....</i>	70
Pharmacological strategies to facilitate transport across the BBB.....	71
<i>2B-TransTM technology.....</i>	71
<i>ABC efflux transporters and penetration of the BBB.....</i>	71
<i>Carrier-mediated drug delivery across the BBB.....</i>	72
<i>G-Technology®.....</i>	73
<i>Glycosylation Independent Lysosomal Targeting.....</i>	73
<i>Inhibition of P-glycoprotein to enhance drug delivery across the BBB.....</i>	73
<i>LipoBridgeTM technology.....</i>	74
<i>Modification of the drug to enhance its lipid solubility.....</i>	74
<i>Monoclonal antibody fusion proteins.....</i>	75
<i>Neuroimmunophilins.....</i>	76
<i>Peptide-mediated transport across the BBB.....</i>	76
<i>Prodrug bioconversion strategies and their CNS selectivity.....</i>	77

<i>Role of the transferrin-receptor system in CNS drug delivery</i>	78
<i>Transport of small molecules across the BBB</i>	78
<i>Transport across the BBB by short chain oligoglycerolipids</i>	78
<i>Transvascular delivery across the BBB</i>	79
<i>Trojan horse approach</i>	79
<i>Use of receptor-mediated transcytosis to cross the BBB</i>	80
Cell-based drug delivery to the CNS.....	81
<i>Activated T lymphocytes</i>	82
<i>Microglial cells</i>	82
<i>Neural stem cells</i>	82
Drug delivery to the CNS by using novel formulations.....	82
<i>Crystalline formulations</i>	82
<i>Liposomes</i>	83
<i>Monoclonal antibodies</i>	84
<i>Microspheres</i>	84
<i>Microbeads</i>	85
Brain-targeted chemical delivery systems.....	85
Nanotechnology-based drug delivery to CNS	86
Nanoparticles for drug delivery across the BBB.....	86
<i>Penetration of BBB by nanoparticles coated with polysorbate 80</i>	87
<i>NanoDel™ technology for crossing the BBB</i>	87
<i>Masking BBB-limiting characteristics by nanotechnology</i>	87
<i>Peptide-nanoparticle conjugates for crossing the BBB</i>	87
<i>Nanovesicles for transport across BBB</i>	88
Nanotechnology-based devices and implants for CNS.....	88
Biochip implants for drug delivery to the CNS	89
Controlled-release microchip.....	89
Retinal implant chip.....	89
Convection-enhanced delivery to the CNS	89
Systemic administration of drugs for CNS effects	90
Sustained and controlled release drug delivery to the CNS.....	90
<i>Fast dissolving oral selegiline</i>	92
Choice of the route of systemic delivery for effect on the CNS disorders.....	92
Methods of delivery of biopharmaceuticals to the CNS	93
Delivery of biopharmaceuticals across the BBB.....	93
Methods of delivery of peptides for CNS disorders.....	93
<i>Challenges for delivery of peptides across the BBB</i>	94
<i>Transnasal administration of neuropeptides</i>	94
<i>Direct delivery of neuropeptides into the brain</i>	94
<i>Alteration of properties of the BBB for delivery of peptides</i>	95
<i>Molecular manipulations of peptides to facilitate transport into CNS</i>	95
<i>CNS delivery of peptides via conjugation to biological carriers</i>	96
<i>Delivery of conopeptides to the brain</i>	96
Delivery of neurotrophic factors to the nervous system.....	96
<i>Systemic administration of NTFs</i>	98
<i>Delivery systems to facilitate crossing of the BBB by NTFs</i>	99
<i>Use of microspheres for delivery of neurotrophic factors</i>	99
<i>Intracerebroventricular injection</i>	99
<i>Direct application of NTFs to the CNS</i>	100
<i>Intrathecal administration</i>	101
<i>Implants for delivery of neurotrophic factors</i>	101
<i>Use of neurotrophic factor mimics</i>	101
Use of microorganisms for therapeutic entry into the brain	103
Bacteriophages as CNS therapeutics.....	103
Intracellular drug delivery in the brain	103
Local factors in the brain affecting drug action	103
Methods for testing drug delivery to the CNS	104
Animal models for testing drug delivery.....	104
Screening for drug-P-gp interaction at BBB.....	104
4. Delivery of Cell, Gene and Antisense Therapies to the CNS	105
Introduction	105
Cell therapy of neurological disorders	105
Methods for delivering cell therapies in CNS disorders.....	105
<i>Encapsulated cells</i>	106
<i>Genetically modified stem cells for metachromatic leukodystrophy</i>	107
<i>CNS neotissue implant</i>	107
<i>CNS delivery of cells by catheters</i>	107
<i>Subarachnoid delivery of stem cells</i>	108
<i>Intravascular administration</i>	108
Gene therapy techniques for the nervous system	109

Introduction	109
Methods of gene transfer to the nervous system	110
AAV vector mediated gene therapy for neurogenetic disorders.....	111
Ideal vector for gene therapy of neurological disorders	111
Promoters of gene transfer.....	111
Routes of delivery of genes to the nervous system	112
<i>Direct injection into CNS</i>	112
<i>Introduction of the genes into cerebral circulation</i>	113
<i>Introduction of genes into cerebrospinal fluid</i>	113
<i>Intravenous administration of vectors</i>	113
<i>Delivery of gene therapy to the peripheral nervous system</i>	114
Cell-mediated gene therapy of neurological disorders	114
<i>Neuronal cells</i>	114
<i>Neural stem cells and progenitor cells</i>	114
<i>Astrocytes</i>	114
<i>Cerebral endothelial cells</i>	115
<i>Implantation of genetically modified encapsulated cells into the brain</i>	115
<i>Genetically modified bone marrow cells</i>	115
Nanoparticles as non-viral vectors for CNS gene therapy	116
Applications of gene therapy for neurological disorders	116
Companies involved in cell/gene therapy of neurological disorders	117
Antisense therapy of CNS disorders	118
Delivery of antisense oligonucleotides to the CNS	119
Delivery of oligonucleotides cross the BBB	120
Cellular delivery systems for oligonucleotides	120
High-flow microinfusion into the brain parenchyma	121
Systemic administration of peptide nucleic acids	121
Introduction of antisense compounds into the CSF Pathways	121
Intrathecal administration of antisense compounds	122
Intracerebroventricular administration of antisense oligonucleotides.....	122
Nanoparticle-based delivery of antisense therapy to the CNS.....	123
Methods of delivery of ribozymes	123
Delivery aspects of RNAi therapy of CNS disorders	124
Delivery of siRNA to the CNS	124
Future drug delivery strategies applicable to the CNS	124
5. Drug Delivery for Treatment of Neurological Disorders	127
Introduction	127
Parkinson's disease	127
Drug delivery systems for Parkinson's disease	128
<i>Methods of delivery of levodopa in PD</i>	130
<i>Duodenal levodopa infusion</i>	130
<i>Sublingual apomorphine</i>	130
<i>Transdermal drug delivery for PD</i>	130
<i>Transdermal dopamine agonists for PD</i>	131
<i>Transdermal administration of other drugs for PD</i>	132
<i>Intracerebral administration of GDNF</i>	132
Cell therapy for PD.....	133
<i>Human dopaminergic neurons for PD</i>	134
<i>Graft survival-enhancing drugs</i>	134
<i>Xenografting porcine fetal neurons</i>	135
<i>Encapsulated cells for PD</i>	135
<i>Stem cells for PD</i>	136
<i>Engineered stem cells for drug delivery to the brain in PD</i>	137
<i>Human retinal pigment epithelium cells for PD</i>	137
<i>Delivery of cells for PD</i>	138
Gene therapy for Parkinson disease.....	138
<i>Rationale</i>	138
<i>Techniques of gene therapy for PD</i>	139
<i>Prospects of gene therapy for PD</i>	143
<i>Companies developing gene therapy for PD</i>	143
RNAi therapy of Parkinson's disease	144
Alzheimer disease	144
Drug delivery for Alzheimer disease	144
Blood-brain partitioning of an AMPA receptor modulator	145
Clearing amyloid through the BBB.....	145
Delivery of the passive antibody directly to the brain.....	146
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	146
Intranasal delivery of nerve growth factor to the brain	146
Nanoparticle-based drug delivery for Alzheimer's disease.....	147
Perispinal etanercept.....	147

Slow release implant of an AChE inhibitor	148
Transdermal drug delivery in Alzheimer's disease.....	148
Trojan-horse approach to prevent build-up of A β aggregates.....	148
Cell and gene therapy for Alzheimer disease.....	149
<i>NGF gene therapy</i>	149
<i>Neprilysin gene therapy</i>	150
RNAi therapy of Alzheimer's disease.....	150
Huntington's disease	151
Treatment of HD.....	151
Gene therapy of HD	151
<i>Encapsulated genetically engineered cellular implants</i>	151
<i>Viral vector mediated administration of neurotrophic factors</i>	152
<i>RNAi therapeutics for the treatment of HD</i>	152
Amyotrophic lateral sclerosis.....	152
Treatment of ALS.....	152
Drug delivery in ALS.....	153
Gene and antisense therapy of amyotrophic lateral sclerosis	154
<i>Neurotrophic factor gene therapies of ALS</i>	154
<i>Antisense therapy of ALS</i>	155
<i>RNAi therapy of amyotrophic lateral sclerosis</i>	155
Drug delivery for CNS involvement in Hunter syndrome	156
Cerebrovascular disease	156
Treatment of stroke	157
Drug delivery in stroke	157
<i>Intraarterial administration of tissue plasminogen activator in stroke</i>	158
Drug delivery for prevention of restenosis of carotid arteries	159
<i>Modified NO donors</i>	159
<i>In-stent restenosis</i>	160
<i>Targeted local anti-restenotic drug delivery</i>	160
<i>Catheter-based drug delivery for restenosis</i>	161
<i>Stents for prevention of restenosis</i>	161
<i>Drug-eluting stents</i>	162
<i>Antisense approach to prevent restenosis</i>	162
Drug-eluting stents for the treatment of intracranial atherosclerosis.....	163
Tissues transplants for stroke.....	163
<i>Transplant of encapsulated tissue secreting neurotrophic factors</i>	163
Cell therapy for stroke.....	163
<i>Stem cell transplant into the brain</i>	164
<i>Immortalized cell grafts for stroke</i>	164
<i>Intravenous infusion of marrow stromal cells</i>	165
<i>Intravenous infusion of umbilical cord blood stem cells</i>	165
<i>Future of cell therapy for stroke</i>	165
Gene therapy of cerebrovascular diseases.....	165
<i>Gene transfer to cerebral blood vessels</i>	166
<i>NOS gene therapy for restenosis</i>	167
Gene therapy for cerebral ischemia	167
<i>Gene therapy of strokes with a genetic component</i>	168
Drug delivery to intracranial aneurysms.....	169
Drug delivery for vasospasm following subarachnoid hemorrhage	169
<i>Intrathecal tissue plasminogen activator</i>	170
<i>Gene therapy for vasospasm</i>	171
Drug delivery in multiple sclerosis.....	172
An electronic device for self injection of interferon beta-1a.....	172
Oral therapies for MS	172
Antisense and RNAi approaches to MS	173
Cell therapy for multiple sclerosis.....	173
<i>Hematopoietic stem cell transplantation for multiple sclerosis</i>	173
<i>Embryonic stem cells and neural precursor cells for MS</i>	174
Gene therapy for multiple sclerosis	174
Drug delivery in epilepsy	175
Routes of administration of antiepileptic drugs.....	175
<i>Controlled-release preparations of carbamazepine</i>	175
<i>Intravenous carbamazepine</i>	176
<i>Various routes of administration of benzodiazepines</i>	176
Methods of delivery of novel antiepileptic therapies	176
<i>Regulated activation of prodrugs</i>	176
<i>Use of neuronal membrane transporter</i>	177
<i>Delivery of the antiepileptic conopeptides to the brain</i>	177
<i>Nasal administration of AEDs</i>	177
<i>Intracerebral administration of AEDs</i>	178
The role of drug delivery in status epilepticus	178

Cell therapy of epilepsy	179
Gene therapy for epilepsy	179
<i>Gene therapy for neuroprotection in epilepsy</i>	180
Concluding remarks on drug delivery in epilepsy.....	180
Drug delivery for pain	181
Intranasal delivery of analgesics	182
<i>Intranasal administration of morphine</i>	182
<i>Intranasal morphine derivatives</i>	183
<i>Intranasal fentanyl</i>	183
<i>Intranasal buprenorphine</i>	184
<i>Intranasal ketamine</i>	184
<i>Intranasal ketorolac</i>	184
Delivery of analgesics by inhalation.....	185
Spinal delivery of analgesics.....	186
<i>Epidural dexamethasone</i>	187
<i>Epidural morphine</i>	188
<i>Relief of pain by intrathecal ziconotide</i>	188
<i>Intrathecal neostigmine</i>	189
<i>Intrathecal prostaglandin antagonists</i>	189
<i>Intrathecal fadolmidine</i>	189
<i>Intrathecal siRNA for relief of neuropathic pain</i>	189
Concluding remarks on intrathecal delivery of analgesic agents	190
Intracerebroventricular drug delivery for pain	190
<i>Delivery of analgesics to the CNS across the BBB</i>	190
Drug delivery for migraine.....	191
Management of migraine	191
Novel drug delivery methods for migraine	192
<i>Nasal formulations for migraine</i>	193
<i>Sublingual spray for migraine</i>	193
<i>Needle-free drug delivery for migraine</i>	193
Relief of spasticity by intrathecal baclofen	194
Drug delivery for traumatic brain injury	194
Cell therapy of traumatic brain injury	194
<i>Gene therapy for traumatic brain injury</i>	195
Drug delivery for spinal cord injury	195
Administration of neurotrophic factors for spinal cord injury	196
Cell therapy for spinal cord injury	196
<i>Transplantation of glial cells for SCI</i>	196
<i>Fetal neural grafts for SCI</i>	196
<i>Embryonic stem cells for SCI</i>	197
<i>Schwann cell transplants for SCI</i>	197
<i>Olfactory glial cells for SCI</i>	197
<i>Marrow stromal cells for SCI</i>	198
<i>Intravenous injection of stem cells for spinal cord repair</i>	198
<i>Combinatorial approach for regeneration in SCI</i>	198
<i>Cell therapy of syringomyelia</i>	199
<i>Gene therapy of spinal cord injury</i>	199
Intrathecal antisense delivery for spinal muscular atrophy	199
Drug delivery in CNS infections.....	200
Drug delivery in neuroAIDS.....	200
Drug delivery for retinal disorders.....	201
<i>Age-related macular degeneration</i>	201
<i>TheraSight ocular brachytherapy system for wet AMD</i>	201
<i>Combretastatin A4P for myopic macular degeneration</i>	202
<i>Gene therapy for AMD</i>	202
<i>Anti-VEGF approach to AMD</i>	203
<i>Delivery of aptamers for treatment of AMD</i>	203
Stem cell therapy for retinitis pigmentosa	203
Proliferative retinopathies	204
Drug delivery for inner ear disorders	204
6. Drug delivery for brain tumors	205
Introduction	205
Methods for evaluation of anticancer drug penetration into brain tumor	205
Innovative methods of drug delivery for glioblastoma multiforme.....	205
Delivery of anticancer drugs across the blood-brain barrier	206
Anticancer agents with increased penetration of BBB.....	206
BBB disruption.....	207
Nanoparticle-based targeted delivery of chemotherapy across the BBB.....	208
Tyrosine kinase inhibitor increases topotecan penetration into CNS	209
Bypassing the BBB by alternative methods of drug delivery	210

Intranasal perillyl alcohol	210
Intraarterial chemotherapy	210
Enhancing tumor permeability to chemotherapy	211
PDE5 inhibitors for increasing BTB permeability	211
Local delivery of therapeutic agents into the brain	211
Biodegradable microspheres containing 5-FU.....	211
Carmustine biodegradable polymer implants	211
Fibrin glue implants containing anticancer drugs	212
Interstitial delivery of dexamethasone for reduction of peritumor edema	212
Magnetically controlled microspheres.....	213
Convection-enhanced delivery	213
CED for receptor-directed cytotoxin therapy	213
CED of topotecan	213
CED of a modified diphtheria toxin conjugated to transferrin	214
CED of nanoliposomal CPT-11.....	214
CED for delivery ¹³¹ I-chTNT-1/B MAb	214
Anticancer drug formulations for targeted delivery to brain tumors	215
Lipid-coated microbubbles as a delivery vehicle for taxol.....	215
Liposomes for drug delivery to brain tumors.....	215
MAbs targeted to brain tumors	215
Targeted delivery of drug-peptide conjugates to GBM.....	216
Multiple targeted drugs for brain tumors	216
Nanoparticles for targeted drug delivery in glioblastoma multiforme	217
Targeted antiangiogenic/apoptotic/cytotoxic therapies.....	218
Introduction of the chemotherapeutic agent into the CSF pathways	219
Intraventricular chemotherapy for meningeal cancer	219
Intrathecal chemotherapy	219
Photodynamic therapy for chemosensitization of brain tumors	220
Nanoparticles for photodynamic therapy of brain tumors.....	220
Innovative delivery of radiotherapy to brain tumors	220
GliaSite Radiation Therapy System.....	220
Boron neutron capture therapy for brain tumors	221
Cell therapy for glioblastoma multiforme.....	221
Mesenchymal stem cells to deliver treatment for gliomas	221
Gene therapy for glioblastoma multiforme.	222
Antiangiogenic gene therapy	223
Anticancer drug delivery by genetically engineered MSCs.....	223
Intravenous gene delivery with nanoparticles into brain tumors.....	223
Ligand-directed delivery of dsRNA molecules targeted to EGFR	224
Neural stem cells for drug/gene delivery to brain tumors	224
Peptides targeted to glial tumor cells.....	225
RNAi gene therapy of brain cancer	225
Single-chain antibody-targeted adenoviral vectors	226
Targeting normal brain cells with an AAV vector encoding interferon-β	226
Treatment of medulloblastoma by suppressing genes in Shh pathway	226
Virus-mediated oncolytic therapy of brain cancer	227
<i>HIV-mediated Oncolysis.....</i>	227
<i>Autophagy by conditionally replicating adenoviruses.....</i>	227
<i>Reovirus-mediated Oncolysis.....</i>	228
<i>Measles virus-mediated oncolysis.....</i>	228
<i>Oncolytic virus targeted to brain tumor stem cells.....</i>	228
<i>Oncolysis with vesicular stomatitis virus</i>	229
<i>Future prospects of viral-mediated oncolysis</i>	229
Vaccination for glioblastoma multiforme	229
7. Markets for Drug Delivery in CNS Disorders.....	231
Introduction	231
Methods of calculation of CNS drug delivery markets	231
Markets for CNS drug delivery technologies	231
Drug delivery share in selected CNS markets.....	232
CNS share of drug delivery technologies	232
Geographical distribution of CNS drug delivery markets	233
Impact of improved drug delivery on CNS drug markets.....	233
Neurodegenerative disorders.....	233
<i>Alzheimer disease</i>	233
<i>Parkinson disease</i>	234
<i>Huntington disease</i>	234
<i>Amyotrophic lateral sclerosis</i>	234
Epilepsy.....	235
Migraine and other headaches	235
Stroke	235

Central nervous system trauma	236
Multiple sclerosis.....	236
Brain tumors	236
Limitations of the current drug delivery technologies for CNS	237
Unmet needs in CNS drug delivery technologies	237
Future strategies for expanding CNS drug delivery markets	238
Education of neurologists	238
Demonstration of the advantages of the newer methods of delivery	239
Rescue of old products by novel drug delivery methods	239
Facilitation of the approval process of new drugs	239
8. Companies	241
Introduction	241
Profiles of companies.....	241
Collaborations.....	318
9. References.....	321

Tables

Table 1-1: Landmarks in the development of drug delivery to the CNS	17
Table 2-1: Proteins expressed at the neurovascular unit	30
Table 2-2: Transporters that control penetration of molecules across the BBB	35
Table 2-3: Enzymes that control the penetration of molecules across the BBB	37
Table 2-4: Factors that increase the permeability of the BBB.....	42
Table 2-5: Diseases that affect the BBB.....	43
Table 3-1: Various methods of drug delivery to the central nervous system	57
Table 3-2: Drugs available for intrathecal administration	66
Table 3-3: Strategies for drug delivery to the CNS across the BBB	68
Table 3-4: Specific inhibitors of P-glycoprotein in clinical development	74
Table 3-5: Molecules attached to Trojan horses injected intravenously for CNS effect.....	79
Table 3-6: Examples of controlled and sustained release drug delivery for CNS disorders	91
Table 3-7: Novel methods of delivery of drugs for CNS disorders	92
Table 3-8: Indications for the clinical applications of NTFs in neurologic disorders	97
Table 3-9: Methods for delivery of neurotrophic factors to the CNS	97
Table 4-1: Methods for delivering cell therapies in CNS disorders.....	106
Table 4-2: Classification of methods of gene therapy.....	109
Table 4-3: Methods of gene transfer as applied to neurologic disorders	110
Table 4-4: Potential indications for gene therapy of neurologic disorders	116
Table 4-5: Companies developing cell/gene therapies for CNS disorders	117
Table 4-6: Methods of antisense delivery as applied to the CNS.....	119
Table 5-1: Strategies for the treatment of Parkinson's disease	127
Table 5-2: Drug delivery systems for Parkinson's disease	129
Table 5-3: Types of cell used for investigative treatment of Parkinson's disease	133
Table 5-4: Status of cell therapies in development for Parkinson's disease	134
Table 5-5: Gene therapy techniques applicable to Parkinson disease	139
Table 5-6: Companies developing gene therapy for Parkinson's disease.....	143
Table 5-7: Classification of pharmacotherapy for Alzheimer disease	144
Table 5-8: Novel drug delivery methods for Alzheimer disease therapies	145
Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	153
Table 5-10: Methods of delivery of therapies in development for ALS	153
Table 5-11: Classification of treatments for stroke	157
Table 5-12: Treatments of stroke involving innovative drug delivery methods	158
Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty	160
Table 5-14: Gene transfer in animal models of carotid artery restenosis	166
Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia	167
Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models.....	168
Table 5-17: Pharmacological agents for treatment of cerebral vasospasm	170
Table 5-18: Gene therapy strategies for vasospasm.....	171
Table 5-19: A classification of drug delivery methods used in management of pain	181
Table 5-20: Spinal administration of drugs for pain	186
Table 5-21: Investigational drugs for pain administered by intrathecal route	186
Table 5-22: Current management of migraine	191
Table 5-23: Novel drug delivery methods for migraine	192
Table 6-1: Innovative methods of drug delivery for glioblastoma multiforme.....	205
Table 6-2: Strategies for gene therapy of malignant brain tumors.....	222
Table 7-1: Share of drug delivery technologies in selected CNS markets: 2011-2021	232
Table 7-2: CNS market share of drug delivery technologies 2011-2021	232
Table 7-3: Value of CNS drug delivery in the major world markets from 2011-2021.....	233

Table 7-4: Limitations of the current drug delivery technologies for CNS.....	237
Table 8-1: Collaborations of companies in CNS drug delivery	318

Figures

Figure 1-1: Interaction of neurotransmitters with receptors	20
Figure 2-1: The neurovascular unit	29
Figure 2-2: Various forms of passage of substances across the blood brain barrier.....	34
Figure 3-1: Routes of drug delivery to the brain	58
Figure 3-2: Use of receptor-mediated transcytosis to cross the BBB	80
Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease	132
Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels	140
Figure 6-1: A concept of targeted drug delivery to GBM across the BBB.....	208
Figure 7-1: Unmet needs in the CNS drug delivery technologies	238